Mineralys Therapeutics (MLYS) Shares Outstanding (2022 - 2026)

Mineralys Therapeutics has reported Shares Outstanding over the past 5 years, most recently at $82.5 million for Q1 2026.

• Shares Outstanding reached $82.5 million in Q1 2026 per MLYS's latest filing, up from $81.5 million in the prior quarter.
• Across five years, Shares Outstanding topped out at $82.5 million in Q1 2026 and bottomed at $5.6 million in Q1 2022.
• Median Shares Outstanding over the past 5 years was $49.6 million (2024), compared with a mean of $44.7 million.
• The largest annual shift saw Shares Outstanding skyrocketed 627.71% in 2023 before it increased 21.05% in 2024.
• Over 5 years, Shares Outstanding stood at $6.4 million in 2022, then soared by 540.79% to $41.1 million in 2023, then grew by 21.12% to $49.8 million in 2024, then skyrocketed by 63.66% to $81.5 million in 2025, then increased by 1.13% to $82.5 million in 2026.
• Business Quant data shows Shares Outstanding for MLYS at $82.5 million in Q1 2026, $81.5 million in Q4 2025, and $79.0 million in Q3 2025.

Peer Comparison